Study summary
A KLK2-targeted T-cell engager lowered PSA by half in about 4 in 10 men
42.4%had PSA fall by at least half (recommended dose)
What was tested
Pasritamig, a bispecific antibody that links immune T cells to the KLK2 protein on prostate cancer cells, in heavily treated castration-resistant disease. No comparison group.
What they found
- PSA fell by at least half in 42.4% at the recommended dose.
- Severe side effects occurred in 9.8%; cytokine release syndrome was rare and mild.
What it means
Now in a phase 3 trial for late-line disease.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.